Articles tagged with Radiation Therapy
A study by University of California, San Diego researchers found that Medicare reimbursement for radiation therapy varies widely among patients with breast, lung, and prostate cancer. Factors such as provider type, location, and clinic type accounted for most of the variation in costs.
Two studies found hypofractionated radiation therapy to have substantially lower rates of acute and short-term toxic effects compared to conventionally fractionated therapy, with improved patient-reported outcomes. The treatment also showed comparable tumor control and lower costs.
University of York scientists identified how tiny regulatory molecules in cells make prostate cancers resistant to radiotherapy. By manipulating these critical micro-RNAs, it may be possible to kill more cancer stem cells and extend the lives of thousands of men.
Researchers have developed a genetic test that analyzes tumor sensitivity to radiation therapy, with findings suggesting metastatic colon tumors are more resistant to radiation than primary tumors. The study suggests personalizing radiation therapy for patients may be possible through this test.
A study of 76 patients with cervical or endometrial cancer found that extended-field IMRT did not increase duodenal toxicity risk, even at high doses. The study confirms the safety of EF-IMRT for treating para-aortic lymph nodes.
Researchers have discovered how combining AKT inhibitors with radiotherapy may improve cancer treatment outcomes. The study found that targeting specific genes can enhance the efficacy of radiotherapy across various cancer types.
A new study by the University of Maryland School of Medicine found that proton therapy significantly reduces toxic side effects in esophageal cancer patients. Proton therapy targets tumors while minimizing harm to surrounding tissues, leading to improved patient outcomes.
Researchers have found that carbon-based nanoparticles can produce low-energy electrons through plasmon excitation, making them more lethal to tumors and potentially inducing focused destruction of cancer cells. This breakthrough could lead to the development of novel types of sensitizers for proton radiotherapy.
A new study found that adding radiation therapy to treatments blocking testosterone's effects can control tumors and save lives for men with node-positive prostate cancer. This combination therapy reduced death rates by 50% compared to hormone therapy alone in patients with regional lymph nodes.
The American Society for Radiation Oncology (ASTRO) has issued a new guideline on definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer, citing 35 years of data to guide current treatment and future research. The guideline recommends RT as the ideal treatment for patients with locally advanced NSCLC.
The ASCENDE-RT1 trial found that permanent radioactive implants (brachytherapy) reduced prostate cancer recurrence by 50% at five years compared to dose-escalated external beam radiotherapy. LDR-PB also showed an overall survival advantage, but with more urinary side effects.
Increasing the dose of radiotherapy for children with intracranial ependymoma can significantly improve their survival rates. Studies show that higher doses above 54 Gy can lead to better overall survival and progression-free survival rates compared to lower doses.
Researchers found that MR tractography can accurately assess prostate cancer treatment response to androgen deprivation and radiation therapy. Higher tract densities indicate gland shrinkage and subsequent fibrosis after therapy.
A UK National Cancer Research Institute trial suggests that a PET scan after chemotherapy can identify patients who don't need additional radiotherapy, reducing late effects. The study found that 90.8% of patients without further treatment remained disease-free compared to 94.6% in the radiotherapy group.
Researchers at MD Anderson Cancer Center have uncovered a novel mechanism by which the tumor suppressor gene p53 regulates PD-L1, allowing non-small cell lung cancer to grow. MicroRNA delivery with existing treatments may represent a new therapeutic approach for lung cancer.
A large study found that fewer than 10% of patients with adverse pathologic features after surgery received postoperative radiotherapy within six months. Despite strong evidence, the utilization of radiation therapy for these patients is declining in the US.
Physicians at UT Southwestern have successfully treated a rare and often deadly complication of kidney cancer using stereotactic body radiation therapy, with similar survival rates to surgery. The innovative approach shows promise as an alternative treatment option for patients resistant to traditional therapies.
Researchers found delayed radiation therapy offers no protective benefit and may increase risk of complications, contradicting the long-held view. Adjuvant therapy soon after prostate removal is effective in curing patients with low-grade disease.
A new study has identified a group of molecules in prostate-cancer cells that can help distinguish which patients should be treated with radiation therapy if rising PSA levels indicate tumor recurrence. MicroRNA patterns, including miR-4516 and miR-601, may predict patient response to radiation therapy.
Researchers found that combining radiation with ipilimumab shrank tumors in some patients. The team also identified the PD-L1 pathway as a mechanism of resistance, suggesting an ideal third treatment to improve response and immunity.
The International Lymphoma Radiation Oncology Group (ILROG) has issued a guideline outlining the use of 3D computed tomography-based radiation therapy planning and volumetric image guidance to treat pediatric Hodgkin lymphoma. The guidelines aim to reduce radiation dose to normal tissue and decrease the risk of late side effects.
A recent study found that nearly a third of women with N2/N3 breast cancer did not receive post-mastectomy radiation therapy (PMRT), which is the standard of care for this patient group. The study evaluated over 57,000 cases and found that socioeconomic factors did not influence PMRT receipt.
A new study published in The Lancet Oncology found that older women with early-stage hormone-receptor positive breast cancers who receive hormone treatment and surgery can safely omit radiotherapy. This group of patients is at low risk of cancer recurrence, making radiotherapy unnecessary.
A new tool assesses radiotherapy-related toxicities in lung cancer patients using patient-reported outcomes, revealing strongest agreement with quality-of-life measures. The study found that clinicians' recorded toxicities underestimated their severity, highlighting the potential for early detection and improved treatment.
A new study found that adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate cancer, reducing cancer deaths by nearly 50 percent. The treatment was also associated with fewer deaths from any cause.
Women undergoing left-side breast cancer radiation therapy can reduce heart exposure by holding their breath, resulting in a 90% disease-free survival rate and a median reduction of 62% in radiation dose. The breath-hold technique also shows a lower risk of ischemic heart disease after 8 years.
A new study reveals that two-thirds of women treated for early-stage breast cancer in the US receive longer radiation therapy than necessary, despite multiple randomized trials and professional society guidelines showing that hypofractionated radiation is clinically effective and less costly.
A recent study published in Cancer journal reveals that older breast cancer patients continue to receive radiation therapy despite evidence suggesting limited benefits. The study analyzed data from a national health database and found that only about one-third of eligible women no longer receive radiation therapy.
Researchers developed an anti-cancer drug that protects normal cells from radiation damage while sparing cancer cells. The compound, RTA 408, increases the effectiveness of radiation therapy in prostate cancer models and has potential applications for treating accidental radiation exposure.
Researchers at the University of Manchester have found that combining AZD3965 with radiotherapy reduces tumour growth in mice and increases anti-tumour effects. The study suggests a new treatment approach for cancer patients by targeting tumours through metabolism
Research found that post-operative radiation therapy improved overall survival for patients with resected NSCLC, with a median survival time of 42 months compared to 38 months without PORT. Factors associated with better survival included female gender, adenocarcinoma histology, and younger age.
Scientists from Queen's University Belfast have made a groundbreaking discovery in attosecond science, tracking ultra-fast electron movement within a nanometer-sized molecule. This research has implications for understanding how radiotherapy kills cancer cells and improving solar cells.
A study published in Practical Radiation Oncology evaluated the use of image-guided radiation therapy (IGRT) in treating pediatric cancers. The results show that IGRT is commonly used to improve localization and precision in radiation delivery, particularly for tumors near sensitive structures or organs.
Researchers found combining immunotherapy with radiotherapy helps the immune system target and destroy cancer cells resistant to initial treatment. This approach improved survival rates and protected mice against disease recurrence.
A recent study found that high-dose radiotherapy did not improve survival rates or delay local relapse in patients with malignant pleural mesothelioma who had undergone chemotherapy and surgery. However, researchers discovered that about 20% of patients expressed the PD-L1 protein, which could be targeted with immunotherapy treatments.
Researchers found modest acute changes in cardiac biomarkers and electrocardiogram findings following thoracic radiation therapy, but no clinically significant cardiac events. The study suggests that longer follow-up and increased dose range may reveal the impact of radiation on late RT-related toxicity.
Researchers present long-term results of RTOG 0236, confirming good primary tumor control and positive 5-year survival rates for patients with inoperable lung cancer. The study found a 40% 5-year survival rate, with seven percent estimated five-year primary tumor failure rate.
A study found that single fraction radiation therapy (SFRT) is equally effective as multiple fraction radiation therapy (MFRT) in improving patients' pain, function, and quality of life, including for those with excluded characteristics. The results support the generalizability of prior randomized controlled trials to real-world practice.
Research found that NSCLC patients who never smoked had a significantly lower risk of developing secondary primary lung cancers (SPLC) compared to current smokers. The study analyzed 1,484 patients and found that five years after diagnosis, current smokers were more likely to develop SPLC.
A new study suggests that combination treatment may not be necessary for all patient populations with the disease. Patients over 65 years old with small tumors and low risk tumor sizes achieved comparable survival after treatment with adjuvant radiation therapy alone, without undergoing endocrine therapy.
A meta-analysis of 757 Stage IV NSCLC patients found that factors such as timing of metastases and lymph node involvement impact overall survival. The study identified three risk groups with different five-year OS rates, and highlighted the importance of identifying patients who are most likely to benefit from aggressive treatments.
A study of 91 prostate cancer patients found that vessel-sparing radiation therapy preserves sexual function without compromising cure rates. Patients who received combination EBRT and brachytherapy reported improved sexual function at five years post-treatment.
Cancer patients with malignant spinal cord compression who receive a single dose of 10 Gy radiation therapy have preserved mobility, comparable to those receiving five daily doses of lower-radiation therapy. The study also found similar changes in bladder function and overall survival rates between the two groups.
A phase I/II trial of hypofractionated radiation therapy found that prostate cancer patients reported similar quality of life, bladder and bowel function before and after treatment. The study's results also indicated that different regimens of hypofractionated RT produced similar outcomes in terms of patient-reported quality of life.
A randomized trial found that radiation therapy (RT) alone is as effective in reducing dysphagia as chemoradiotherapy (CRT), allowing patients to forgo chemotherapy. The study also demonstrated comparable survival prognosis between the two groups, highlighting a potential simpler treatment option.
A randomized phase II trial found that Manuka honey was not effective in reducing esophagitis pain during radiation therapy for lung cancer patients. The study enrolled 163 patients who received either standard supportive care or Manuka honey supplements, but showed no significant differences in pain levels.
Research presented at ASTRO's 56th Annual Meeting found no association between radiation therapy and increased risk of lymphedema in women with clinically node-negative breast cancer. The study results provide reassurance for breast cancer patients regarding the impact of radiation therapy on lymphedema risk.
A new radiotherapy strategy for treating advanced small-cell lung cancer significantly prolongs long-term survival and reduces cancer recurrence in the chest. The study found that patients treated with thoracic radiation therapy had a 50% lower risk of cancer recurrence compared to those who did not receive it.
A study of over 41,000 patients with stage I and II Hodgkin's Disease found that those receiving consolidated radiation therapy had a higher 10-year survival rate of 84 percent compared to 76 percent for non-RT recipients. The data also showed a decrease in RT utilization, highlighting ongoing disparities in treatment.
A shorter course of androgen deprivation therapy (ADT) has been found to improve the quality of life for high-risk prostate cancer patients, with faster recovery times and better outcomes compared to a longer 36-month ADT regimen. The study analyzed data from 561 patients who received radiation therapy and long-term ADT.
Researchers found that high levels of VEGF-A and TGF-β1 before treatment correlated with lower survival rates and less complete tumor regression. A blood test for these proteins could help predict patients' pathological response and disease-free survival rates, allowing for more personalized treatment plans.
Researchers from Montefiore and Einstein present findings on radiation therapy duration, dosing recommendations, and predictive indicators for clinical outcomes in locally-advanced cancers. The studies focus on improving personalized cancer care and overcoming treatment barriers.
Kids Konnected and the Breast and Gyn Health Project in California will each receive $8,500 awards to support their work assisting cancer patients and their families. The organizations will also be featured at ASTRO's Annual Meeting in San Francisco.
Seven physicians receive funding to advance radiation oncology research, including studies on cancer biology, physics, and treatment outcomes. Recipients will focus on improving radiation therapy and enhancing patient care.
Researchers at MD Anderson Cancer Center have discovered that protein ZEB1 helps breast cancer cells repair DNA damage caused by radiation therapy, making them more resistant to treatment. This finding has significant implications for the development of new treatments targeting ZEB1 and other proteins involved in radioresistance.
A new triple therapy combining two immunotherapies and targeted radiation has prolonged the survival of mice with glioblastoma brain cancer by up to 67 days. The treatment induces an immune response against tumors, creating long-term immunity.
A study published in the British Journal of Cancer found that bladder cancer patients with high levels of the protein HIF-1α are more likely to benefit from a treatment called CON, which makes radiotherapy more effective. High levels of the protein were linked to better survival rates when patients had radiotherapy and CON.
A two-step decision tree analysis was used to evaluate and distill existing quality standards, guidelines, and recommendations in radiation therapy. The study identified duplicate standards and gaps, achieving substantial agreement among evaluators.
Three plant-derived compounds, caffeic acid, rosmarinic acid, and trans-cinnamic acid, have been found to protect human skin cells from gamma radiation-induced damage during cancer radiotherapy. The compounds reduced reactive oxygen species and DNA damage by up to 40% and 15%, respectively.
ASTRO Gold Medal winners Mary K. Gospodarowicz, Leonard L. Gunderson, and Nancy J. Tarbell will receive the award for their outstanding work in research, clinical care, teaching, and service. They have made significant contributions to advancing radiation oncology, improving patient outcomes, and promoting global health.